Everand Logo

Welcome to Everand!

  • STAT

    Opinion: Drug pricing conversations must take the cost of innovation into consideration

    Congressional and presidential efforts to lower drug prices today must also tackle the fundamental question of how much innovation we are willing to pay for to create tomorrow's new drugs.
    by Craig Garthwaite and Benedic Ippolito Jan 11, 2019 5 minutes
    Sen. Bernie Sanders speaks as (from left) Sen. Richard Blumenthal (D-Conn.), Sen. Cory Booker (D-N.J.), Rep. Ilhan Omar (D-Minn.), Rep. Joe Neguse (D-Colo.), and Rep. Ro Khanna (D-Calif.) listen during a news conference on prescription drugs on Thursday in Washington.

    Midterm elections have ushered in a decidedly split 116th Congress. Yet the desire to lower U.S. pharmaceutical spending, which now exceeds $450 billion a year and dwarfs that of any other developed nation, is likely to continue uniting some strange bedfellows. Lawmakers from both side of the aisle are doing a disservice to Americans by uniting behind populist drug pricing proposals that ignore the harsh realities of drug development in favor of simplicity and sloganeering.

    Consider the unlikely coalition of Sen. Bernie Sanders (I-Vt.), Rep. Ro Khanna (D-Calif.), Rep. Elijah Cummings (D-Md.), and President Donald Trump calling to tie U.S. drug prices to those of our international peers.

    Just Thursday, Sanders, Cummings, and Khanna aimed at drugs that are considered “excessively priced” — those whose U.S. price exceeds the average amount paid by five other developed countries. The secretary of health and human services would be charged with ending patent protection for such drugs, opening

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
    Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
    Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.

    Related